

Special Issue

Omics in Ovarian Cancer

Message from the Guest Editors

Omics studies including, but not limited to, proteomics, radiomics, genomics, radiogenomics, transcriptomics, and metabolomics rely on the high-throughput identification and quantification of molecules or imaging biomarkers, as an expression of complex biological mechanisms. Integrative omics in ovarian cancer may represent opportunities for identifying driver genes, as well as molecular signatures, to be used for prognostication and for guiding the path to targeted therapies. This Special Issue will cover the current state-of-the-art of different omics studies in ovarian cancer and will highlight their role for a better understanding of this pathology covering a range of topics from basic to preclinical and clinical aspects.

PD Dr. Med. Stefania Rizzo
Dr. Med. Lucia Manganaro

Guest Editors

Dr. Stefania Rizzo

1. Clinica di Radiologia Ente Ospedaliero Cantonale (EOC), Istituto Imaging della Svizzera Italiana, Via Tesserete 46, 6900 Lugano, Switzerland

2. Facoltà di Scienze biomediche, Università della Svizzera italiana (USI), Via G. Buffi 13, 6900 Lugano, Switzerland

Dr. Lucia Manganaro

Department of Radiological, Oncological, and Pathological Sciences, Sapienza, University of Rome, 00161 Rome, Italy

Deadline for manuscript submissions

closed (15 September 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/54271

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)